Solid Biosciences Inc. (SLDB): Free Cash Flow
-$157.44M
Year ended 2025-12-31
-$187.81M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$157.44M | n/m | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | -$100.67M | n/m | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | -$95.69M | n/m | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | -$100.99M | n/m | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | -$79.05M | n/m | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | -$57.50M | n/m | 2023-03-23, From 2020-01-01 |
| 2019-12-31 | -$97.10M | n/m | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | -$77.97M | n/m | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | -$45.50M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$20.51M | n/a | 2019-03-13, From 2016-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | -$157.44M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$121.71M | n/m |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | -$139.73M | n/m |
| Agenus Inc (AGEN) | 2025-12-31 | -$77.20M | n/m |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | -$104.72M | n/m |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | -$100.72M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$50.19M | n/m |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | -$89.47M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | -$74.09M | n/m |
Compare SLDB, DBVT, TCRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗